

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Indoleamine-pyrrole 2,3 dioxygenase (IDO1; INDO; IDO)	<p>Studies in cell culture and in mice suggest that hydroxyamidine analogs could treat IDO-expressing cancers. High throughput screening and <i>in vitro</i> assays identified a hydroxyamidine compound that was a selective low-micromolar inhibitor of IDO. In normal mice the compound reduced plasma levels of kynurenine, a measure of IDO inhibition. In mouse models of melanoma, the compound reduced tumor growth compared with no treatment.</p> <p>Incyte Corp. expects to begin Phase I testing of a hydroxyamidine IDO inhibitor to treat cancer in 2010. NewLink Genetics Corp.'s IDO inhibitor, 1-methyl-D-tryptophan (1-MT), is in Phase I testing to treat relapsed or refractory solid tumors.</p> <p>SciBX 2(24); doi:10.1038/scibx.2009.971 Published online June 18, 2009</p>	<p>Patented; available for licensing Contact: Pam Murphy, Incyte Corp., Wilmington, Del. e-mail: pmurphy@incyte.com</p>	<p>Yue, E. <i>et al. J. Med. Chem.</i>; published online June 9, 2009; doi:10.1021/jm900518f Contact: Andrew P. Combs, Incyte Corp., Wilmington, Del. e-mail: acombs@incyte.com</p>